ISIS 416858

DRUG2 trials

Sponsors

Ionis Pharmaceuticals, Inc.

Conditions

End-stage Renal Disease (ESRD)

Phase 2

A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

CompletedNCT02553889

Ionis Pharmaceuticals, Inc.End-stage Renal Disease (ESRD)

Start: 2015-10-31End: 2016-11-30Updated: 2016-12-13

A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis

CompletedNCT03358030

Ionis Pharmaceuticals, Inc.End-stage Renal Disease (ESRD)

Start: 2017-12-26End: 2019-07-10Updated: 2023-01-20

Related Papers

Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI<sub>Rx</sub> in Patients With ESRD.

2021-11-2463 citations